验证数据展示
经过测试的应用
| Positive WB detected in | SH-SY5Y cells, HeLa cells, mouse testis tissue |
| Positive FC detected in | SH-SY5Y cells |
推荐稀释比
| 应用 | 推荐稀释比 |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:4000 |
| Flow Cytometry (FC) | FC : 0.40 ug per 10^6 cells in a 100 µl suspension |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
产品信息
22192-1-AP targets CHRNB4 in WB, ELISA applications and shows reactivity with human, mouse samples.
| 经测试应用 | WB, ELISA Application Description |
| 文献引用应用 | WB |
| 经测试反应性 | human, mouse |
| 文献引用反应性 | human |
| 免疫原 | CHRNB4 fusion protein Ag16767 种属同源性预测 |
| 宿主/亚型 | Rabbit / IgG |
| 抗体类别 | Polyclonal |
| 产品类型 | Antibody |
| 全称 | cholinergic receptor, nicotinic, beta 4 |
| 别名 | Neuronal acetylcholine receptor subunit beta-4, CHRNB 4 |
| 计算分子量 | 498 aa, 56 kDa |
| 观测分子量 | 48-60 kDa |
| GenBank蛋白编号 | BC096080 |
| 基因名称 | CHRNB4 |
| Gene ID (NCBI) | 1143 |
| RRID | AB_11232227 |
| 偶联类型 | Unconjugated |
| 形式 | Liquid |
| 纯化方式 | Antigen affinity purification |
| UNIPROT ID | P30926 |
| 储存缓冲液 | PBS with 0.02% sodium azide and 50% glycerol , pH 7.3 |
| 储存条件 | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
实验方案
| Product Specific Protocols | |
|---|---|
| WB protocol for CHRNB4 antibody 22192-1-AP | Download protocol |
| FC protocol for CHRNB4 antibody 22192-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
发表文章
| Species | Application | Title |
|---|---|---|
Mar Drugs Differential Expression of Nicotine Acetylcholine Receptors Associates with Human Breast Cancer and Mediates Antitumor Activity of αO-Conotoxin GeXIVA. | ||
Eur J Pharmacol Identification of nicotinic acetylcholine receptor subunits in different lung cancer cell lines and the inhibitory effect of alpha-conotoxin TxID on lung cancer cell growth. | ||
Cancers (Basel) An Integrated Genomic Strategy to Identify CHRNB4 as a Diagnostic/Prognostic Biomarker for Targeted Therapy in Head and Neck Cancer.
| ||
Mar Drugs Cervical Cancer Correlates with the Differential Expression of Nicotinic Acetylcholine Receptors and Reveals Therapeutic Targets. |
